Qureshi Rahila, Alaparthi Malini Devi, Eligati Prathyusha Sai, Hasan Razvi Syed Rizwan, Walvekar Komal Paresh, Afraa Mohammad, Sagurthi Someswar Rao
Drug Design & Molecular Medicine Laboratory, Department of Genetics & Biotechnology, Osmania University, Hyderabad, Telangana-500007, India.
Bioinformation. 2020 Nov 30;16(11):942-948. doi: 10.6026/97320630016942. eCollection 2020.
Leishmaniasis is one of the most neglected diseases with high morbidity and mortality rate. Severe side effects with existing drug and lack of proper vaccine encouraged us to design alternative models to combat the disease. We showed that PP1 of Leishmania donovani mediates immunomodulation in host macrophages needed for parasite survival. Therefore, it is of interest to report the molecular docking analysis of 512 isoflavone derivatives with the phosphatase 1 protein from Leishmania donovani to highlight compound 362 (5-hydroxy-5-{9-[2-methoxy-2-(2-methylfuran-3-yl) ethyl]-1H, 3H, 4H, 10bH-pyrano[4,3-c]chromen-3-yl}pentanoic acid) having good binding features and acceptable ADMET properties for further consideration.
利什曼病是发病率和死亡率极高的最被忽视的疾病之一。现有药物的严重副作用以及缺乏合适的疫苗促使我们设计替代模型来对抗该疾病。我们发现杜氏利什曼原虫的PP1介导了寄生虫生存所需的宿主巨噬细胞中的免疫调节。因此,报道512种异黄酮衍生物与杜氏利什曼原虫磷酸酶1蛋白的分子对接分析,以突出显示具有良好结合特性和可接受的药物代谢动力学性质的化合物362(5-羟基-5-{9-[2-甲氧基-2-(2-甲基呋喃-3-基)乙基]-1H, 3H, 4H, 10bH-吡喃并[4,3-c]色烯-3-基}戊酸)以供进一步研究,这很有意义。